6029 Stock Overview
Artra Group Corporation provides support services for acupuncture, moxibustion, and orthopedic clinics in Japan.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 5/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Artra Group Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | JP¥167.00 |
52 Week High | JP¥412.00 |
52 Week Low | JP¥161.00 |
Beta | 0.75 |
1 Month Change | -5.11% |
3 Month Change | -9.73% |
1 Year Change | -9.24% |
3 Year Change | -48.46% |
5 Year Change | -55.23% |
Change since IPO | -50.54% |
Recent News & Updates
Recent updates
Shareholder Returns
6029 | JP Healthcare | JP Market | |
---|---|---|---|
7D | 1.2% | -0.3% | -1.0% |
1Y | -9.2% | 2.8% | 27.9% |
Return vs Industry: 6029 underperformed the JP Healthcare industry which returned 2.8% over the past year.
Return vs Market: 6029 underperformed the JP Market which returned 27.9% over the past year.
Price Volatility
6029 volatility | |
---|---|
6029 Average Weekly Movement | 3.2% |
Healthcare Industry Average Movement | 3.8% |
Market Average Movement | 4.1% |
10% most volatile stocks in JP Market | 8.1% |
10% least volatile stocks in JP Market | 2.2% |
Stable Share Price: 6029 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6029's weekly volatility has decreased from 9% to 3% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2005 | 156 | Hiroyuki Kyuse | www.artra-group.co.jp |
Artra Group Corporation provides support services for acupuncture, moxibustion, and orthopedic clinics in Japan. It operates through two segments, Acupuncture and Moxibustion Hospital Support Business, and Toy Sales Business. The company offers billing services; and HONEY-STYLE, a word-of-mouth / reservation system for acupuncture and moxibustion clinics.
Artra Group Corporation Fundamentals Summary
6029 fundamental statistics | |
---|---|
Market cap | JP¥1.69b |
Earnings (TTM) | JP¥53.00m |
Revenue (TTM) | JP¥4.50b |
32.0x
P/E Ratio0.4x
P/S RatioIs 6029 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
6029 income statement (TTM) | |
---|---|
Revenue | JP¥4.50b |
Cost of Revenue | JP¥3.03b |
Gross Profit | JP¥1.46b |
Other Expenses | JP¥1.41b |
Earnings | JP¥53.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 14, 2024
Earnings per share (EPS) | 5.22 |
Gross Margin | 32.53% |
Net Profit Margin | 1.18% |
Debt/Equity Ratio | 106.2% |
How did 6029 perform over the long term?
See historical performance and comparison